May 12, 2017 / 12:19 PM / 5 months ago

BRIEF-Eiger BioPharma Q1 loss per share $1.34

May 12 (Reuters) - Eiger Biopharmaceuticals Inc

* Eiger biopharmaceuticals reports first quarter 2017 financial results

* Q1 loss per share $1.34

* Eiger biopharmaceuticals - as of march 31, 2017, co had cash, cash equivalents and short term marketable securities of $49.0 million

* Eiger biopharmaceuticals inc - research and development expenses for q1 of 2017 were $7.4 million compared to $4.8 million for q1 of 2016

* Eiger biopharmaceuticals inc - expenses on track; cash runway extends through mid-2018

* Eiger biopharmaceuticals inc - fda meeting planned in q4 for lonafarnib hdv program, sees interim data from limt hdv study in q4 at aasld Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below